Drugs / ISM6331
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06566079 | Dec 2024 → Aug 2027 expected | malignant mesothelioma, metastatic malignant neoplasm | InSilico Medicine | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISM6331 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06566079 ↗ |
| Route | Oral | “Dosage form: Capsule for oral administration.” NCT06566079 ↗ |